Viktig informasjon i saken hentes i sanntid direkte fra EPO sitt register (European Patent Register), slik at du enkelt og raskt får oversikt i saken.
Beskrivelse Verdi
Saken / databasen er sist oppdatert info  
Tittel 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
Status
Hovedstatus
Detaljstatus
Ikke i kraft info Patent opphørt Ikke betalt årsavgift
Patentnummer NO/EP3672949
Europeisk (EP) publiserings nummer EP3672949
EP levert
EP søknadsnummer 18772885.2
EP meddelt
Prioritet 2017.08.23, US 201762549225 P
Sakstype Europeisk
Løpedag
Utløpsdato
Allment tilgjengelig
Validert i Norge
Innehaver Novartis AG (CH)
Oppfinner BECKWITH, Rohan Eric John (US) .... se mer/flere nedenfor
Fullmektig ZACCO NORWAY AS (NO)
Lenke til European patent Register Informasjon i saken, dokumenter og patentfamilie
Patentfamilie Se i Espacenet

EPO translation logo


Se forsidefigur og sammendrag i Espacenet

T3

Beskrivelse

Krav

Patentkrav1. Forbindelse med formel (I'):eller et farmasøytisk akseptabelt salt, hydrat, solvat, stereoisomer eller tautomer derav, hvori:X1 er CR3;er valgfritt en dobbeltbinding når X1 er CR3 og R3 er fraværende;hver R1 er uavhengig (C1-C6)-alkyl, (C1-C6)-haloalkyl, (C1-C6)-hydroksyalkyl eller halogen, ellerto R1 sammen med karbonatomene som de er bundet til, danner en 5- eller 6-leddet heterosykloalkylring, ellerto R1, når de befinner seg på naboliggende atomer, sammen med atomene som de er bundet til, danner en (C6-C10)-arylring eller en 5- eller 6-leddet heteroarylring omfattende 1 til 3 heteroatomer valgt blant O, N og S;R2 er (C1-C6)-alkyl, -C(O)(C1-C6)-alkyl, -C(O)(CH2)0-3(C6-C10)-aryl, -C(O)O(CH2)0-3(C6-C10)-aryl, (C6-C10)-aryl, 5- eller 6-leddet heteroaryl omfattende 1 til 3 heteroatomer valgt blant O, N og S, eller (C3-C8)-sykloalkyl, hvor alkylen er valgfritt substituert med én eller flere R4; og arylen, heteroarylen og sykloalkylen er valgfritt substituert med én eller flere R5, ellerR1 og R2, når de befinner seg på naboliggende atomer, sammen med atomene som de er bundet til, danner en 5- eller 6-leddet heterosykloalkylring;R3 er H eller R3 er fraværende når er en dobbeltbinding;hver R4 velges uavhengig blant -C(O)OR6, -C(O)NR6R6', -NR6C(O)R6', halogen, -OH, -NH2, CN, (C6-C10)-aryl, 5- eller 6-leddet heteroaryl omfattende 1 til 4 heteroatomer valgt blant O, N og S, (C3-C8)-sykloalkyl og en 5- til 7-leddet heterosykloalkylring omfattende 1 til 3 heteroatomer valgt blant O, N og S, hvor aryl-, heteroaryl-, sykloalkyl- og heterosykloalkylgruppene er valgfritt substituert med én eller flere R7; hver R5 velges uavhengig blant (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C1-C6)-alkoksy, (C1-C6)-haloalkyl, (C1-C6)-haloalkoksy, (C1-C6)-hydroksyalkyl, halogen, -OH, -NH2, CN, (C3-C7)-sykloalkyl, 5- til 7-leddet heterosykloalkyl omfattende 1 til 3 heteroatomer valgt blant O, N og S, (C6-C10)-aryl og 5- eller 6-leddet heteroaryl omfattende 1 til 3 heteroatomer valgt blant O, N og S, eller to R5, når de befinner seg på naboliggende atomer, sammen med atomene som de er bundet til, danner en (C6-C10)-arylring eller en 5- eller 6-leddet heteroarylring omfattende 1 til 3 heteroatomer valgt blant O, N og S, valgfritt substituert med én eller flere R10, ellerto R5, når de befinner seg på naboliggende atomer, sammen med atomene som de er bundet til, danner en (C5-C7)-sykloalkylring eller en 5- til 7-leddet heterosykloalkylring omfattende 1 til 3 heteroatomer valgt blant O, N og S valgfritt substituert med én eller flere R10;R6 og R6', er hver uavhengig H, (C1-C6)-alkyl eller (C6-C10)-aryl;hver R7 velges uavhengig blant (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C1-C6)-alkoksy, (C1-C6)-haloalkyl, (C1-C6)-haloalkoksy, -C(O)R8, -(CH2)0-3C(O)OR8, -C(O)NR8R9, -NR8C(O)R9, - NR8C(O)OR9, -S(O)pNR8R9, -S(O)pR12, (C1-C6)-hydroksyalkyl, halogen, -OH, -O(CH2)1-3CN, -NH2, CN, -O(CH2)0-3(C6-C10)-aryl, adamantyl, -O(CH2)0-3-5- eller 6-leddet heteroaryl omfattende 1 til 3 heteroatomer valgt blant O, N og S, (C6-C10)-aryl, monosyklisk eller bisyklisk 5- til 10-leddet heteroaryl omfattende 1 til 3 heteroatomer valgt blant O, N og S, (C3-C7)-sykloalkyl, og 5- til 7-leddet heterosykloalkyl omfattende 1 til 3 heteroatomer valgt blant O, N og S, hvor alkylen er valgfritt substituert med én eller flere R11, og arylen, heteroarylen og heterosykloalkylen er valgfritt substituert med én eller flere substituenter som hver uavhengig velges blant halogen, (C1-C6)-alkyl, (C1-C6)-haloalkyl og (C1-C6)-alkoksy, ellerto R7 sammen med karbonatomet de er bundet til, danner en =(O), ellerto R7, når de befinner seg på naboliggende atomer, sammen med atomene som de er bundet til, danner en (C6-C10)-arylring eller en 5- eller 6-leddet heteroarylring omfattende 1 til 3 heteroatomer valgt blant O, N og S, valgfritt substituert med én eller flere R10, ellerto R7 sammen med atomene som de er bundet til, danner en (C5-C7)-sykloalkylring eller en 5- til 7-leddet heterosykloalkylring omfattende 1 til 3 heteroatomer valgt blant O, N og S, valgfritt substituert med én eller flere R10; R8 og R9 er hver uavhengig H eller (C1-C6)-alkyl;hver R10 velges uavhengig blant (C1-C6)-alkyl, (C1-C6)-alkoksy, (C1-C6)-haloalkyl, (C1-C6)-haloalkoksy, (C1-C6)-hydroksyalkyl, halogen, -OH, -NH2 og CN, eller to R10 sammen med karbonatomet de er bundet til, danner en =(O);hver R11 velges uavhengig blant CN, (C1-C6)-alkoksy, (C6-C10)-aryl og 5- til 7-leddet heterosykloalkyl omfattende 1 til 3 heteroatomer valgt blant O, N og S, hvor arylen og heterosykloalkylen er valgfritt substituert med én eller flere substituenter hver uavhengig valgt blant (C1-C6)-alkyl, (C1-C6)-alkoksy, (C1-C6)-haloalkyl, (C1-C6)-haloalkoksy, (C1-C6)-hydroksyalkyl, halogen, -OH, -NH2 og CN;R12 er (C1-C6)-alkyl, (C1-C6)-haloalkyl, (C6-C10)-aryl eller 5- til 7-leddet heterosykloalkyl omfattende 1 til 3 heteroatomer valgt blant O, N og S;Rx er H eller D;p er 0, 1 eller 2;n er 0, 1 eller 2;n1 er 1 eller 2, hvor n n1 ≤ 3; ogq er 0, 1, 2, 3 eller 4.2. Forbindelse ifølge krav 1, som har en formel (I):eller et farmasøytisk akseptabelt salt, hydrat, solvat, stereoisomer eller tautomer derav, hvori:X1 er CR3;er valgfritt en dobbeltbinding når X1 er CR3 og R3 er fraværende;hver R1 er uavhengig (C1-C6)-alkyl, (C1-C6)-haloalkyl, (C1-C6)-hydroksyalkyl eller halogen;R2 er (C1-C6)-alkyl, (C6-C10)-aryl, 5- eller 6-leddet heteroaryl omfattende 1 til 3 heteroatomer valgt blant O, N og S, eller (C3-C8)-sykloalkyl, hvor alkylen er valgfritt substituert med én eller flere R4; og arylen, heteroarylen og sykloalkylen er valgfritt substituert med én eller flere R5;R3 er H eller R3 er fraværende når er en dobbeltbinding; hver R4 velges uavhengig blant -C(O)OR6, -C(O)NR6R6, -NR6C(O)R6', (C6-C10)-aryl, 5- eller 6-leddet heteroaryl omfattende 1 til 3 heteroatomer valgt blant O, N og S, (C3-C8)-sykloalkyl og 5- til 7-leddet heterosykloalkyl omfattende 1 til 3 heteroatomer valgt blant O, N og S, hvor aryl-, heteroaryl-, sykloalkyl- og heterosykloalkylgruppene er valgfritt substituert med én eller flere R7;hver R5 velges uavhengig blant (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C1-C6)-alkoksy, (C1-C6)-haloalkyl, (C1-C6)-haloalkoksy, (C1-C6)-hydroksyalkyl, halogen, -OH, -NH2, CN, (C3-C7)-sykloalkyl, 5- til 7-leddet heterosykloalkyl omfattende 1 til 3 heteroatomer valgt blant O, N og S, (C6-C10)-aryl og 5- eller 6-leddet heteroaryl omfattende 1 til 3 heteroatomer valgt blant O, N og S, eller to R5, når de befinner seg på naboliggende atomer, sammen med atomene som de er bundet til, danner en (C6-C10)-arylring eller en 5- eller 6-leddet heteroarylring omfattende 1 til 3 heteroatomer valgt blant O, N og S, valgfritt substituert med én eller flere R10, ellerto R5, når de befinner seg på naboliggende atomer, sammen med atomene som de er bundet til, danner en (C5-C7)-sykloalkylring eller en 5- til 7-leddet heterosykloalkylring omfattende 1 til 3 heteroatomer valgt blant O, N og S valgfritt substituert med én eller flere R10;R6 og R6 er hver uavhengig H eller (C1-C6)-alkyl;hver R7 velges uavhengig blant (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C1-C6)-alkoksy, (C1-C6)-haloalkyl, (C1-C6)-haloalkoksy, -C(O)R8, -C(O)OR8, -C(O)NR8R9, -NR8C(O)R9, (C1-C6)-hydroksyalkyl, halogen, -OH, -NH2, CN, (C6-C10)-aryl, 5- eller 6-leddet heteroaryl omfattende 1 til 3 heteroatomer valgt blant O, N og S, (C3-C7)-sykloalkyl og 5- til 7-leddet heterosykloalkyl omfattende 1 til 3 heteroatomer valgt blant O, N og S, ellerto R7, når de befinner seg på naboliggende atomer, sammen med atomene som de er bundet til, danner en (C6-C10)-arylring eller en 5- eller 6-leddet heteroarylring omfattende 1 til 3 heteroatomer valgt blant O, N og S, valgfritt substituert med én eller flere R10, ellerto R7, når de befinner seg på naboliggende atomer, sammen med atomene som de er bundet til, danner en (C5-C7)-sykloalkylring eller en 5- til 7-leddet heterosykloalkylring omfattende 1 til 3 heteroatomer valgt blant O, N og S valgfritt substituert med én eller flere R10;R8 og R9 er hver uavhengig H eller (C1-C6)-alkyl; hver R10 velges uavhengig blant (C1-C6)-alkyl, (C1-C6)-alkoksy, (C1-C6)-haloalkyl, (C1-C6)-haloalkoksy, (C1-C6)-hydroksyalkyl, halogen, -OH, -NH2 og CN;Rx er H eller D;n er 1 eller 2; ogq er 0, 1, 2, 3 eller 4, fortrinnsvis er q 0, 1 eller 2.3. Forbindelse ifølge krav 1 eller 2, hvor n er 1.4. Forbindelse ifølge krav 1 eller 2, hvor n er 2.5. Forbindelse ifølge et hvilket som helst av de foregående krav, hvor X1 er CH.6. Forbindelse ifølge et hvilket som helst av de foregående krav, hvor Rx er H.7. Forbindelse ifølge krav 1, som har en formel (Ia), formel (Ib), formel (Ic) eller formel (Id):8. Forbindelse ifølge et hvilket som helst av de foregående krav, hvor R2 er (C6-C10)-aryl eller (C3-C8)-sykloalkyl, hvor arylen og sykloalkylen er valgfritt substituert med én til tre R5, fortrinnsvis er R2 (C6-C10)-aryl eller (C3-C8)-sykloalkyl.9. Forbindelse ifølge et hvilket som helst av kravene 1-7, hvor R2 er (C1-C6)-alkyl valgfritt substituert med én til tre R4.10. Forbindelse ifølge krav 1, valgt blant: 3-(5-(1-etylpiperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-propylpiperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(syklopropylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-isobutylpiperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(syklobutylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(oksazol-2-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(tiazol-2-ylmetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(syklopentylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-((5-klortiofen-2-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((2-klortiazol-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(sykloheksylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(1-okso-5-(1-(2-(pyrrolidin-1-yl)etyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((tetrahydro-2H-pyran-4-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-fenetylpiperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(3-fluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(3-klorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(2-fluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(2-klorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(1-okso-5-(1-(2-(piperidin-1-yl)etyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((3,5-dimetylisoksazol-4-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1,3-dimetyl-1H-pyrazol-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((6-metylpyridin-2-yl)metyl)piperidin-4-yl)-1-oksoisindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(3-morfolinopropyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(2,6-difluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(2,6-diklorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(3,5-difluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(3,5-dibrombenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(3-klor-5-fluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(2,5-difluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(2,5-diklorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 4-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)benzonitril;3-(5-(1-(4-(hydroksymetyl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(3,4-diklorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(4-klor-2-fluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(2-klor-4-fluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)benzonitril;3-(5-(1-(2,3-difluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 2-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)benzonitril;3-(5-(1-(4-metoksybenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(2,5-dimetylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(3,4-dimetylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(2,4-dimetylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1H-indazol-4-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1H-benzo[d]imidazol-2-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-isopropylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; metyl 5-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)furan-2-karboksylat;3-(5-(1-(naftalen-2-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(kinolin-2-ylmetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(naftalen-1-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1-metyl-1H-benzo[d]imidazol-2-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(4-(trifluormetoksy)benzyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-(1H-pyrrol-1-yl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-(1H-1,2,4-triazol-1-yl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(3-(trifluormetoksy)benzyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(2-(trifluormetoksy)benzyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-benzylpiperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(pyridin-2-ylmetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; 3-(1-okso-5-(1-(pyridin-3-ylmetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; 3-(1-okso-5-(1-(pyridin-4-ylmetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; 3-(1-okso-5-(1-(pyrimidin-5-ylmetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(1-fenyletyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-(fluormetyl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(3,4-difluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 2-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)pyrimidin-5-karbonitril;3-(5-(1-(4-etylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(2-metoksybenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-((2-metoksypyrimidin-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(3-fluor-4-metylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-(difluormetyl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;4-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)benzamin;4-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)benzosyre;3-(5-(1-(3-(difluormetyl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)benzosyre;3-(1-okso-5-(1-(4-propylbenzyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; 3-(1-okso-5-(1-(4-(trifluormetyl)benzyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-(difluormetoksy)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((5-(trifluormetyl)pyridin-2-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(3-(difluormetoksy)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(2-(difluormetoksy)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-syklobutylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((2,3-dihydrobenzo[b][1,4]dioksin-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((2,3-dihydrobenzo[b][1,4]dioksin-6-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-(tert-butyl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-isobutylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; N-(4-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)fenyl)acetamid;3-(5-(1-((2,2-difluorbenzo[d][1,3]dioksol-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((3,4-dihydro-2H-benzo[b][1,4]dioksepin-7-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(4-(tert-pentyl)benzyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-([1,1'-bifenyl]-4-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-(1H-pyrazol-1-yl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-(1H-imidazol-1-yl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(3-(1H-pyrazol-1-yl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-sykloheksylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(pyrimidin-2-ylmetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-brombenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(4-klorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(3,5-diklorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(4-klor-3-fluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(3-klor-4-fluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(2,4-difluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(3-metoksybenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(benzo[c][1,2,5]oksadiazol-5-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(2-syklopropylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-((1,3-dihydroisobenzofuran-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(2-(trifluormetyl)benzyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(3-isopropoksybenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(4-(tiofen-3-yl)benzyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-syklopentylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(4-(pyrrolidin-1-yl)benzyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-fluorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(2,4-diklorbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(1-okso-5-(1-(kinolin-8-ylmetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-((1-metyl-1H-pyrazol-4-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1H-pyrazol-4-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1-metyl-1H-pyrazol-3-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1H-pyrazol-3-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1H-pyrrol-3-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1H-imidazol-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1-etyl-1H-pyrazol-3-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((2-aminopyrimidin-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((6-aminopyridin-3-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-((5-amino-1-metyl-1H-pyrazol-4-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((6-metylimidazo[2,1-b]tiazol-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(imidazo[1,2-a]pyrazin-3-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-([1,2,4]triazolo[1,5-a]pyridin-5-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(pyrazolo[1,5-a]pyridin-4-ylmetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1,4-dimetyl-1H-imidazol-2-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(benzo[d]tiazol-5-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(pyrazolo [1,5-a]pyrimidin-6-ylmetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(imidazo [1,2-a]pyrimidin-3-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(imidazo[1,2-a]pyrimidin-2-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1-syklobutyl-1H-1,2,3-triazol-4-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-2-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1H-indol-2-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1H-indazol-6-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1H-pyrrolo[2,3-b]pyridin-3-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)benzamid;3-(5-(1-((1H-pyrrolo[2,3-b]pyridin-6-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-((3,4-dihydro-2H-benzo[b][1,4]tiazin-6-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((2-(pyrrolidin-1-yl)pyrimidin-5-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((2-(tert-butyl)tiazol-4-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((2-(tiofen-2-yl)tiazol-5-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((5-syklopropyl-1H-pyrazol-3-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((2-morfolinopyrimidin-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((3-fenyl-1H-pyrazol-4-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((6-metyl-1H-indol-3-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;metyl 4-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)-1H-pyrrol-2-karboksylat;3-(1-okso-5-(1-((3-(pyridin-3-yl)-1H-pyrazol-4-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((5-(pyridin-2-yl)-1H-pyrazol-3-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(3,5-difluor-4-hydroksybenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(2-metylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(4-metylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(3,5-dimetylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-((2S)-1-benzyl-2-metylpiperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-((2R)-1-benzyl-2-metylpiperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-benzyl-2-metylpiperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-metyl-1,2,3,6-tetrahydropyridin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((5,6,7,8-tetrahydronaftalen-1-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(azepan-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-((R)-azepan-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-((S)-azepan-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((1,2,3,4-tetrahydronaftalen-1-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;metyl 2-(4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)acetat;3-(1-okso-5-(1-fenylpiperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(3-metylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(2,6-dimetylbenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((5,6,7,8-tetrahydronaftalen-2-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;etyl 2-(4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)acetat; tert-butyl 2-(4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)acetat;2-(4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)eddiksyre; 3-(1-okso-5-(1-(3,3,3-trifluorpropyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;2-(4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)-N-fenylacetamid;3-(5-(1-(3-fluorpropyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; tert-butyl 4-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)benzoat;3-(5-(1-benzyl-3,3-dimetylpiperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-benzyl-3-metylpiperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(2-hydroksy-1-fenyletyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-((S)-1-benzylazepan-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-benzyl-2,5-dihydro-1H-pyrrol-3-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-benzyl-2-oksopiperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-benzyl-1,2,3,4-tetrahydrokinolin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1-benzyl-1H-tetrazol-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((5-fenyl-1,3,4-oksadiazol-2-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(benzo[d]tiazol-2-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((3-(pyridin-2-yl)-1H-pyrazol-5-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((R)-2-hydroksy-1-fenyletyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1-metyl-1H-indazol-3-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1,2,4-oksadiazol-3-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-hydroksy-3-((4-metylpiperazin-1-yl)metyl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;2-(4-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)fenyl)acetonitril;3-(5-(1-((7-hydroksy-2-metylpyrazolo[1,5-a]pyrimidin-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(2,2-difluor-1-fenyletyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((3-fluorbisyklo[1.1.1]pentan-1-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(2-fluor-1-fenyletyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((4-okso-3,4-dihydrotieno [3,2-d]pyrimidin-2-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(kinolin-4-ylmetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(3,5-bis(trifluormetyl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;6-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)pikolinonitril;2-(4-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)fenoksy)acetonitril;3-(5-(1-((1H-indazol-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(2,2-difluoretyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-((7-metyl-4-okso-4H-pyrido[1,2-a]pyrimidin-2-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;benzyl 4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-karboksylat;3-(1-okso-5-(1-(2-fenylacetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; 3-(1-okso-5-(1-(2,2,2-trifluor-1-fenyletyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-(5-metylbenzo[d]tiazol-2-yl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(isokinolin-1-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-(4-metoksypiperidin-1-yl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-(isopropyltio)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((S)-1-fenyletyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; 2-(4-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)fenyl)eddiksyre;3-(5-(1-((7-fluorkinolin-2-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((2-amino-4-(trifluormetyl)tiazol-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)-1,2,4-oksadiazol-5-karboksamid; 3-(5-(1-(3-(morfolinosulfonyl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;4-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)-N,N-dimetylbenzensulfonamid;3-(1-okso-5-(1-(tiazol-4-ylmetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; 3-(1-okso-5-(1-(kinoksalin-6-ylmetyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-(tert-butyl)benzoyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-((4-fluorbenzyl)oksy)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((3-metylisoksazol-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(isoksazol-3-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((R)-1-fenyletyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-(4-(metoksymetyl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((S)-2-hydroksy-1-fenyletyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(fenylsulfonyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-((5-metyl-3-fenylisoksazol-4-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-((difluormetyl)sulfonyl)benzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-(2,2,2-trifluoretyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion; metyl 2-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)oksazol-4-karboksylat;3-(1-okso-5-(1-(4-(pyridin-2-ylmetoksy)benzyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-acetylpiperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-benzylpyrrolidin-3-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; (R)-3-(5-((R)-1-benzylazepan-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; (S)-3-(5-((S)-1-benzylazepan-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-benzylazepan-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-metyl-2,3,6,7-tetrahydro-1H-azepin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(8-benzyl-8-azabisyklo[3.2.1]oktan-3-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(8-azabisyklo[3.2.1]oktan-3-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-acetyl-1,2,5,6-tetrahydropyridin-3-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;(R)-3-(5-((R)-1-acetylpyrrolidin-3-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(oktahydroindolizin-7-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;(R)-3-(5-((S)-1-benzylazepan-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-((R)-1-benzylazepan-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-acetyl-2,5-dihydro-1H-pyrrol-3-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-metylazepan-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;(S)-3-(5-((R)-1-benzylazepan-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; (S)-3-(5-((R)-1-acetylpyrrolidin-3-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-((6-isopropoksypyridin-3-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((1-fenyl-1H-pyrazol-5-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(4-etoksybenzyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(1-okso-5-(1-((1-fenyl-1H-pyrazol-4-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1-isopropyl-1H-pyrazol-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-(isotiazol-5-ylmetyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1-isopropyl-1H-pyrazol-4-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; 3-(5-(1-((1H-pyrazol-5-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((5-isopropoksypyridin-2-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((1-(pyridin-3-yl)-1H-pyrazol-5-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;3-(1-okso-5-(1-((1-(pyridin-3-yl)-1H-pyrazol-4-yl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;5-((4-(2-(2,6-dioksopiperidin-3-yl)-1-oksoisoindolin-5-yl)piperidin-1-yl)metyl)-2-fluorbenzonitril;3-(5-(1-((5-fluorpyridin-2-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;3-(5-(1-((1-etyl-3-(pyridin-3-yl)-1H-pyrazol-4-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;trans-3-(1-okso-5-(1-((4-(trifluormetyl)sykloheksyl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;cis-3-(1-okso-5-(1-((4-(trifluormetyl)sykloheksyl)metyl)piperidin-4-yl)isoindolin-2-yl)piperidin-2,6-dion;trans-3-(5-(1-((4-metoksysykloheksyl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion; og3-(5-(1-((6-metoksypyridin-2-yl)metyl)piperidin-4-yl)-1-oksoisoindolin-2-yl)piperidin-2,6-dion;eller et farmasøytisk akseptabelt salt, hydrat, solvat, stereoisomer eller tautomer derav.11. Forbindelse ifølge krav 1, hvori forbindelsen er:eller et farmasøytisk akseptabelt salt, hydrat, solvat, stereoisomer eller tautomer derav.12. Farmasøytisk sammensetning som omfatter en forbindelse ifølge et hvilket som helst av kravene 1-11 eller et farmasøytisk akseptabelt salt, hydrat, solvat, stereoisomer eller tautomer derav, og en farmasøytisk akseptabel bærer eller eksipiens, valgfritt videre omfattende i det minste ett ytterligere farmasøytisk middel. 13. Forbindelse ifølge et hvilket som helst av kravene 1-11 eller et farmasøytisk akseptabelt salt, hydrat, solvat, stereoisomer eller tautomer derav for anvendelse som et medikament.14. Forbindelse ifølge et hvilket som helst av kravene 1-11 eller et farmasøytisk akseptabelt salt, hydrat, solvat, stereoisomer eller tautomer derav eller farmasøytisk sammensetning ifølge krav 12 for anvendelse i behandlingen av kreft.15. Forbindelse eller farmasøytisk sammensetning for anvendelse ifølge krav 14, hvor kreften velges blant en kreft for hvilken immunresponsen er mangelfull eller er en immunogen kreft, ikke-småcellet lungekreft (NSCLC), melanom, trippel negativ brystkreft (TNBC), nasofaryngeal kreft (NPC), mikrosatellittstabil tarmkreft (mssCRC), tymom, karsinoid, akutt myelogen leukemi og gastrointestinal stromal tumor (GIST).16. Forbindelse ifølge et hvilket som helst av kravene 1-11 eller et farmasøytisk akseptabelt salt, hydrat, solvat, stereoisomer eller tautomer derav for anvendelse i behandlingen av en IKZF2-avhengig sykdom eller lidelse.17. Farmasøytisk kombinasjon som omfatter en forbindelse ifølge et hvilket som helst av kravene 1-11 eller et farmasøytisk akseptabelt salt, hydrat, solvat, stereoisomer eller tautomer derav, og ett eller flere ytterligere terapeutiske midler.
Hva betyr A1, B, B1, C osv? info
Innehaver i EP:
Novartis AG
Lichtstrasse 35 4056 Basel CH
Novartis Institutes for BioMedical Research Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 US
Novartis Institutes for BioMedical Research Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 US
Novartis Institutes for BioMedical Research Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 US
Novartis Institutes for BioMedical Research Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 US
Novartis Institutes for BioMedical Research Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 US
Novartis Institutes for BioMedical Research Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 US
Fullmektig i Norge:
ZACCO NORWAY AS
Postboks 488 0213 OSLO NO ( OSLO kommune, Oslo fylke )

Org.nummer: 982702887
Din referanse: V454832NO00
  • Foretaksnavn:
  • Foretaksform:
  • Næring:
  • Forretningsadresse:
     

Kilde: Brønnøysundregistrene
Fullmektig i EP:
Reid, Stephanie Marie
Novartis Pharma AG Lichtstrasse 35 4056 Basel CH

2017.08.23, US 201762549225 P

EP-A1- 3 061 758 (B1)

WO-A1-2006/028964 (B1)

WO-A2-2015/160845 (B1)

WO-A1-2018/140809 (B1)

WO-A1-2018/071606 (B1)

Statushistorie

Liste over statusendringer i sakshistorikk
Hovedstatus Beslutningsdato, detaljstatus
Patent opphørt Ikke betalt årsavgift
EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
EP under behandling Forespørsel om å gjøre EP patent gyldig er mottatt

Korrespondanse

Liste over sakshistorikk og korrespondanse
Dato Type korrespondanse Journal beskrivelse
Utgående EP Opphørt for ikke betalt årsavgift (3206)
11-01 Via Altinn-sending EP Opphørt for ikke betalt årsavgift (3206)
Utgående EP Påminnelse om ikke betalt årsavgift (3331) (PTEP3672949)
10-01 Via Altinn-sending EP Påminnelse om ikke betalt årsavgift (3331) (PTEP3672949)
Innkommende EP Publiseringsdokument fra EPO
09-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
08-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
07-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
06-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Utgående EP Varsel om betaling av første årsavgift (3319) (PTEP3672949)
05-01 Via Altinn-sending EP Varsel om betaling av første årsavgift (3319) (PTEP3672949)
Innkommende EP Publiseringsdokument fra EPO
04-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Utgående EP Registreringsbrev (3210) (PTEP3672949)
03-01 Brev UT EP Registreringsbrev (3210) (PTEP3672949)
Innkommende Søknadsskjema Patent
01-01 Søknadsskjema Patent Søknadsskjema Patent
01-02 Fullmakt Novartis AG-General PoA 455137
01-03 EP oversettelse V454832NO00-claims-NO 471551
01-04 Hovedbrev V454832NO00-Validation_Request 471552
Innkommende EP Publiseringsdokument fra EPO
02-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO

Til betaling:

Betalingshistorikk:

Liste av betalinger
Beskrivelse / Fakturanummer Betalingsdato Beløp Betaler Status
Årsavgift 6. avg. år (EP) 2023.08.09 2000 CPA GLOBAL LIMITED Betalt og godkjent
32303105 expand_more 2023.03.21 5500 ZACCO NORWAY AS Betalt
Denne oversikten kan mangle informasjon, spesielt for eldre saker, om tilbakebetaling, internasjonale varemerker og internasjonale design.

Lenker til publikasjoner og Norsk Patenttidende (søkbare tekstdokumenter)

Allment tilgjengelig patentsøknad
Hva betyr A1, B, B1, C osv? info
Kapitler uten data er fjernet. Melding opprettet: 01.05.2025 05:08:21